Quick Answer
Nautilus Biotechnology, Inc. reported Total Assets of $191.11 million for the year ending 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -21.3% in Total Assets from 2024 to 2025.
- This data is from Nautilus Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $211.3 thousand | Q3 2020: $150.95 million | Q1 2021: $150.50 million | Q2 2021: $393.28 million | Q3 2021: $385.35 million | Q1 2022: $384.67 million | Q2 2022: $371.71 million | Q3 2022: $359.31 million | Q1 2023: $345.88 million | Q2 2023: $330.77 million | Q3 2023: $318.34 million | Q1 2024: $288.65 million | Q2 2024: $272.75 million | Q3 2024: $259.70 million | Q1 2025: $227.69 million | Q2 2025: $213.19 million | Q3 2025: $200.92 million.
- Over the full 6 years of available data (2020 to 2025), Nautilus Biotechnology, Inc.'s Total Assets has grown by 124.8%.
- Historical annual values: Fiscal year 2025: $191.11 million | Fiscal year 2024: $242.74 million | Fiscal year 2023: $305.57 million | Fiscal year 2022: $350.05 million | Fiscal year 2021: $398.45 million | Fiscal year 2020: $85.01 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: